Sangamo (SGMO): Company Short-Term Debts

Sangamo - graphic logo of issuer SGMO

Sangamo Therapeutics (SGMO) generates revenue by developing gene therapy methods and tools for editing the code of life, securing funding through collaborations with pharmaceutical industry behemoths. The business focuses on combating severe genetic pathologies using advanced molecular approaches. This market trend visualized in monetary format on GURU.Markets with a value of 0.00 confirms the company's leadership in the field of zinc finger nucleases and its robust patent protection.

SGMO sangamo.com Company Short-Term Indebtedness (07/04/2022 - 05/09/2026)

Summary analytical data breakdowns for Sangamo BioSciences (SGMO)

- current quotes and average value forecast:
Price Chart Sangamo Therapeutics, Inc.|SGMO - Analyst Median Target
- stock exchange capitalization data:
Market Capitalization Sangamo Therapeutics, Inc.|SGMO - Enterprise Value
- business book valuation details:
Net Assets per Single Share Sangamo Therapeutics|SGMO - Accounting Capitalization|Market Capitalization to Book Value Ratio sangamo.com|SGMO - Company Balance Sheet Assets
- debt level and financial liquidity data:
Total Debt to Capital Sangamo Therapeutics|SGMO - Long-Term Debt to Capital|Short-Term Debt to Equity Sangamo Therapeutics|SGMO - Company Total Debt|Debt to Book Capitalization Ratio Sangamo Therapeutics, Inc.|SGMO - Long-Term Debt|Company Current Liabilities Sangamo Therapeutics|Quick Liquidity Indicator sangamo.com
- earnings and multiples data:
SGMO - Profit After Payment of Taxes
Initial company analysis:SGMO - Sangamo Therapeutics, Inc.
Manufactured products of Sangamo Therapeutics

The operational resilience of Sangamo Therapeutics (SGMO) is directly reflected in its total short-term debt. This indicator aggregates all obligations maturing within one year, determining current liquidity. Analyzing payment dynamics allows for the identification of hidden refinancing costs and capital risks. For a biopharmaceutical vendor with deep B2B integration into R&D chains, this metric confirms financial stability while scaling its AI platform. Low volatility in this series indicates high asset quality.

Main competitors

TEM - Company Short-Term Debt|Short-Term Debt Volume Qiagen NV QGEN|IONS: Company Short-Term Debts|Repligen Inc. (RGEN) - Company Short-Term Debts|Company Short-Term Debt Avidity Biosciences|Company Short-Term Indebtedness CRSP (crisprtx.com)|Company Short-Term Debts WGS|Ultragenyx Pharmaceutical Inc. (RARE) - Short-Term Indebtedness|Company Short-Term Debts BEAM (Beam Therapeutics Corp)|Company Short-Term Debts Sarepta Corp SRPT|TWST - Company Short-Term Debt|10xgenomics.com (TXG) - Company Current Liabilities|Intellia Therapeutics, Inc. (NTLA) - Company Short-Term Debt|Short-Term Debt Stoke Therapeutics Inc (STOK)|Company Current Liabilities BLFS|WVE: Company Short-Term Loans and Borrowings|Company Current Liabilities MAZE (Maze Therapeutics Inc)|Amount of Current Liabilities SION|Company Short-Term Debts PRME (Prime Medicine)|Company Short-Term Loans and Borrowings TSHA|uniQure Corp - Company Short-Term Debts|Short-Term Debt MeiraGTx Corp|REGENXBIO Inc. (RGNX) - Company Short-Term Debt|solidbio.com - Company Short-Term Loans and Borrowings|OCGN (Ocugen) - Company Short-Term Debts|Company Short-Term Debts Pacific Biosciences of California, Inc.|Company Short-Term Debt Benitec (BNTC)|DSGN: Current Liabilities|Company Short-Term Debts RCKT (Rocket Pharmaceuticals)|4dmoleculartherapeutics.com (FDMT) - Short-Term Debt|LXEO: Company Current Liabilities|KRRO - Company Short-Term Debts|EDIT (Editas) - Company Current Liabilities|SLN: Amount of Current Liabilities|PRQR (ProQR) - Company Short-Term Debts|Codexis Bio (CDXS) - Short-Term Debt Volume|Company Short-Term Debts NAUT|Company Current Liabilities Metagenomi Inc. MGX|Company Short-Term Debt Precision BioSciences DTIL|Short-Term Debt Volume Generation Bio Co (GBIO)|BOLD - Company Short-Term Debt|Short-Term Debt Volume Exicure, Inc. XCUR|IMNN: Company Short-Term Debts|Short-Term Indebtedness Phio Pharmaceuticals Corp. PHIO|Company Short-Term Debt Mustang Bio Inc|Company Current Liabilities TransCode (RNAZ)|Company Short-Term Debt Bionano Genomics, Inc. (BNGO)|APDN - Short-Term Debt|Company Short-Term Debts BLUE (bluebird bio)|IPA: Company Short-Term Indebtedness|OMGA - Company Short-Term Debt|OMIC (Singular Genomics Corp) - Company Short-Term Indebtedness|RGLS: Company Short-Term Debts|syros.com (SYRS) - Company Short-Term Debts|Company Short-Term Debt Telesis Bio|TRACON Pharmaceuticals Inc. (TCON) - Short-Term Debt Volume|Company Short-Term Debts UBX